@Sanctuary_Bio Biotech equities have longer-duration cash flows and are disproportionately affected by rapid rate hikes just like long-duration bonds. But, if rates have reached stasis the biotech equity premium will always be attractive.
@hardimanjames This is the crux, ultimately subsidizing VC returns. Great summary! Now do VCs find another bank of choice for venture debt or do valuations compress?
@LifeSciVC We seek contagion to drive our companies' value and then curse it when it wreaks havoc. Sadly there are many more followers than leaders. The Rapport letter put it well, just signed!
@BowTiedBiotech@JonahLupton Yeah, banks' sensitivity to long-duration assets dropping when the Fed hikes rates makes further hikes a potential trigger for systemic stress.
@msuster This exposes VC's concentration issue. The operational contagion risk from ~50% of VCs using SVB (from their latest update deck) is one thing, but the echo chamber effect in the industry is what turned the spark into a blaze.
@msuster Totally agree the 2008-again narrative is lazy. From SVB's latest update, their LTV of 43% and quality of assets is a far cry from the excessive risk profiles of banks in 2008.
Dan Orlovsky didn’t just send off a ‘praying for Damar Hamlin’ tweet.
He paused during NFL Live, bowed his head, and prayed.
Powerful, brave, and genuine. 🙏
Shocked to see Berkshire Hathaway's largest allocation is 40%. Hopefully the concentration says more about $aapl than $brk.a. Stay diversified my friends!
https://t.co/IiNVRmIQdh